Aileron Therapeutics Announces Acquisition of Lung Therapeutics
Acquisition includes multiple clinical stage, orphan pulmonary disease candidates, including LTI-03, a Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis (IPF)
Related news for (ALRN)
- Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
- aileron therapeutics to present previously announced data from the phase 1b clinical trial evaluating low-dose lti-03 in idiopathic pulmonary fibrosis (ipf) at the 22nd international colloquium on lung and airway fibrosis
- aileron therapeutics completes enrollment in cohort 2 of the ongoing phase 1b clinical trial evaluating lti-03 in idiopathic pulmonary fibrosis (ipf)
- aileron therapeutics reports second quarter 2024 financial results and business highlights
- Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024